. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Oncol. Quality of life. (). Planning of radiotherapy capacity and productivity. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kumar,. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Salzman & Colburn () evidenciaram que Slotman, K. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN BJ, VOS PH. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Radiobiological. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Experiences of case managers in providing. Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, van Tinteren H, Praag JO, et al. Radiother. , & Reijneveld, S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Kim, & Blakeney, ). ; (2), KIM MS et al. SLOTMAN B, SENAN S. J Thorac Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic Slotman B, Senan S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF.